ES2530574T3 - Biomarcadores asociados a la nefropatía - Google Patents

Biomarcadores asociados a la nefropatía Download PDF

Info

Publication number
ES2530574T3
ES2530574T3 ES10735453T ES10735453T ES2530574T3 ES 2530574 T3 ES2530574 T3 ES 2530574T3 ES 10735453 T ES10735453 T ES 10735453T ES 10735453 T ES10735453 T ES 10735453T ES 2530574 T3 ES2530574 T3 ES 2530574T3
Authority
ES
Spain
Prior art keywords
nephropathy
combination
biomarkers
biomarker
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10735453T
Other languages
English (en)
Inventor
Tzu-Ling Tseng
Ching-Fang Lu
Wei-Ya Lin
Tsai-Wei Hsu
Mary Ya-Ping Yeh
Yi-Ting Chen
Chwei-Shiun Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industrial Technology Research Institute
Original Assignee
Industrial Technology Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industrial Technology Research Institute filed Critical Industrial Technology Research Institute
Application granted granted Critical
Publication of ES2530574T3 publication Critical patent/ES2530574T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

Un método de diagnóstico de la nefropatía en un sujeto, que comprende: obtener una muestra de orina de un sujeto que se sospecha que tiene nefropatía, determinar en la muestra de orina un nivel de un biomarcador o de una combinación de biomarcadores seleccionado del grupo que consiste en: (i) receptor-2 similar a Ig asociado a leucocitos o uno de sus fragmentos, y (ii) una combinación del receptor-2 similar a Ig asociado a leucocitos o uno de sus fragmentos y de la alfa- 1-glicoproteína ácida o uno de sus fragmentos, en donde el fragmento de receptor-2 similar a Ig asociado a leucocitos es DFLELLVKGTVPGTEASGFDAP (SEQ ID NO:1) y el fragmento de alfa-1-glicoproteína ácida es GQEHFAHLLILRDTKTYMLAFDVNDEKNWGLS (SEQ ID NO:2); y evaluar si el sujeto tiene nefropatía basándose en el nivel del biomarcador o de la combinación de biomarcadores, en donde un aumento en el nivel del biomarcador o de la combinación de biomarcadores, en comparación con un punto de referencia que representa el nivel del mismo biomarcador o de la combinación de biomarcadores en un sujeto sin nefropatía, indica que el sujeto tiene nefropatía, en donde el punto de referencia es el punto medio entre el nivel medio del biomarcador o de la combinación de biomarcadores en un grupo de pacientes con nefropatía y el de un grupo de sujetos sin nefropatía.
ES10735453T 2009-01-28 2010-01-27 Biomarcadores asociados a la nefropatía Active ES2530574T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14778509P 2009-01-28 2009-01-28
PCT/CA2010/000096 WO2010085878A1 (en) 2009-01-28 2010-01-27 Biomarkers associated with nephropathy

Publications (1)

Publication Number Publication Date
ES2530574T3 true ES2530574T3 (es) 2015-03-03

Family

ID=42395075

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10735453T Active ES2530574T3 (es) 2009-01-28 2010-01-27 Biomarcadores asociados a la nefropatía

Country Status (12)

Country Link
US (5) US20100209948A1 (es)
EP (1) EP2391653B8 (es)
JP (1) JP5524241B2 (es)
CN (1) CN102300875B (es)
BR (1) BRPI1007483B1 (es)
CA (1) CA2748852C (es)
DK (1) DK2391653T3 (es)
ES (1) ES2530574T3 (es)
MX (1) MX2011007810A (es)
PT (1) PT2391653E (es)
TW (1) TWI397687B (es)
WO (1) WO2010085878A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2623517T3 (en) * 2009-01-28 2015-11-23 Ind Tech Res Inst Urine and serum biomarkers associated with diabetic nephropathy
KR101732706B1 (ko) * 2015-06-05 2017-05-04 압타바이오 주식회사 신증 진단용 마커로서의 sh3yl1의 용도
PL3469372T3 (pl) * 2016-06-10 2023-12-04 Warszawski Uniwersytet Medyczny Sposoby diagnozowania i monitorowania z wykorzystaniem białek moczu jako markerów nefropatii IgA
CN119165152A (zh) * 2019-01-17 2024-12-20 国立大学法人冈山大学 IgA肾病发病可能性的判断方法及试剂盒

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4640909A (en) * 1985-05-07 1987-02-03 J. T. Baker Chemical Company Bonded phase of silica and carboalkoxyalkyl silanes for solid phase extraction
JP4602482B2 (ja) * 1996-05-24 2010-12-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 組織再生のモジュレーター
EP0948623B1 (en) * 1996-12-06 2010-01-27 Schering Corporation Isolated mammalian monocyte cell genes; related reagents
US6140076A (en) * 1996-12-06 2000-10-31 Schering Corporation Ig superfamily `dlair` receptors expressed in monocytes
AUPP784398A0 (en) * 1998-12-21 1999-01-21 Monash University Kidney disease detection and treatment
US20040029175A1 (en) * 1998-12-21 2004-02-12 Comper Wayne D. Method for kidney disease detection
IL143892A0 (en) * 1998-12-21 2002-04-21 Univ Monash Kidney disease detection and treatment
EP1191096B1 (en) * 1999-06-28 2011-10-12 Yusuke Nakamura Ovel protein and dna thereof
SI1509618T1 (sl) * 2002-05-13 2009-02-28 Arexis Ab Avtoimunska stanja in defekti NADPH oksidaze
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
DE602004022150D1 (de) * 2003-03-27 2009-09-03 Childrens Hosp Medical Center Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
CA2591142A1 (en) * 2004-12-15 2007-05-10 Beth Israel Deaconess Medical Center, Inc. Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy
US20060257481A1 (en) * 2005-04-21 2006-11-16 Decode Genetics Ehf. Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy
EP2004850A2 (en) * 2006-03-08 2008-12-24 Universitair Medisch Centrum Utrecht Interfering in activation of an immune cell by influencing interaction of lair and collagen.
US7662578B2 (en) * 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
CA2660286A1 (en) * 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
WO2008021431A2 (en) * 2006-08-14 2008-02-21 Xdx, Inc. Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
JP5363984B2 (ja) * 2006-10-13 2013-12-11 メタボロン インコーポレイテッド 代謝年齢に関するバイオマーカー及びその使用方法
US20080187944A1 (en) * 2007-01-31 2008-08-07 Appa Rao Allam Butyrylcholinesterase as a marker of low-grade systemic inflammation
EP2137538B1 (en) * 2007-03-21 2014-04-09 Bioporto Diagnostics A/s Diagnostic test for renal injury
US9000134B2 (en) * 2007-05-11 2015-04-07 Wallace B. Haigh Reagent and kit for early diagnosis of kidney disease
DK2623517T3 (en) * 2009-01-28 2015-11-23 Ind Tech Res Inst Urine and serum biomarkers associated with diabetic nephropathy

Also Published As

Publication number Publication date
US20110081668A1 (en) 2011-04-07
WO2010085878A1 (en) 2010-08-05
BRPI1007483B1 (pt) 2021-11-30
US20110081667A1 (en) 2011-04-07
EP2391653A1 (en) 2011-12-07
CN102300875B (zh) 2014-07-16
BRPI1007483A2 (pt) 2016-02-16
CN102300875A (zh) 2011-12-28
US9442120B2 (en) 2016-09-13
EP2391653B8 (en) 2015-09-30
MX2011007810A (es) 2011-09-30
US20130266976A1 (en) 2013-10-10
EP2391653B1 (en) 2014-12-31
US8470547B2 (en) 2013-06-25
CA2748852C (en) 2019-05-28
US20100209948A1 (en) 2010-08-19
US20110086372A1 (en) 2011-04-14
DK2391653T3 (en) 2015-02-09
JP5524241B2 (ja) 2014-06-18
TW201033615A (en) 2010-09-16
PT2391653E (pt) 2015-02-13
CA2748852A1 (en) 2010-08-05
TWI397687B (zh) 2013-06-01
JP2012516430A (ja) 2012-07-19
EP2391653A4 (en) 2012-06-27

Similar Documents

Publication Publication Date Title
ES2506116T3 (es) Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo
GB2467704A (en) Methods of monitoring conditions by sequence analysis
PH12012500850A1 (en) Methods for diagnosing irritable bowel syndrome
ES2572377T3 (es) Método para la detección de la presencia, o el riesgo, de cáncer de vejiga
MX368394B (es) Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.
MX355020B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
EA201290629A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
NZ610356A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2829881A3 (en) Diagnostic for colorectal cancer
BR112013003391A2 (pt) biomarcadores de câncer pancreático e usos dos mesmos
WO2011021041A3 (en) Survival prognostic assay
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
NZ625423A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ624614A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010096154A3 (en) Compositions and methods for diagnosis and prognosis of colorectal cancer
EP1989551A4 (en) METHOD OF DETECTING OR DIAGNOSING NEURODEGENERATIVE DISEASE OR DISEASE
ATE501267T1 (de) Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs
CO6311041A2 (es) Un metodo para determinar y monitorear un cancer ginecologico que comprende la determinacion de niveles de biomarcadores en una muestra biologica
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
CL2011001944A1 (es) Metodo de diagnostico in vitro de un sujeto con sindrome de intestino irritable (ibs).
NZ599773A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
RU2019104870A (ru) Комбинированный тест на наличие колоректального рака
MX2020010825A (es) Sistema y metodo para determinar la salud pulmonar.
HK1232238A1 (zh) 检测人类骨膜蛋白的新型测定
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento